Fiscal Period | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
Revenue | 3,749.21 | 3,453.71 | 3,251.72 | 3,278.03 |
Total Revenue | 3,749.21 | 3,453.71 | 3,251.72 | 3,278.03 |
Costof Revenue Total | 1,512.30 | 1,457.10 | 1,394.28 | 1,482.14 |
Gross Profit | 2,236.91 | 1,996.61 | 1,857.44 | 1,795.89 |
Selling/ General/ Admin Expenses Total | 996.64 | 1,026.91 | 991.00 | 981.81 |
Depreciation/ Amortization | 66.66 | 69.54 | 65.62 | 68.04 |
Interest Exp( Inc) Net- Operating Total | 0.13 | 0.14 | 0.14 | 0.14 |
Other Operating Expenses Total | 60.64 | 61.01 | 52.24 | 47.06 |
Total Operating Expense | 2,636.37 | 2,778.00 | 2,513.91 | 2,599.03 |
Operating Income | 1,112.84 | 675.71 | 737.81 | 679.00 |
Interest Inc( Exp) Net- Non- Op Total | 137.58 | 115.05 | 89.29 | 64.87 |
Gain( Loss)on Saleof Assets | 4.69 | 20.58 | 9.67 | 31.72 |
Other Net | 4.77 | 4.85 | -0.37 | 3.45 |
Net Income Before Taxes | 1,259.88 | 816.19 | 836.40 | 779.05 |
Provisionfor Income Taxes | 332.30 | 226.23 | 228.76 | 398.28 |
Net Income After Taxes | 927.58 | 589.96 | 607.64 | 380.77 |
Net Income Before Extra Items | 927.58 | 589.96 | 607.64 | 380.77 |
Net Income | 927.58 | 589.96 | 610.69 | 1,694.72 |
Income Availableto Com Excl Extra Ord | 927.58 | 589.96 | 607.64 | 380.77 |
Income Availableto Com Incl Extra Ord | 927.58 | 589.96 | 610.69 | 1,694.72 |
Diluted Net Income | 927.58 | 589.96 | 610.69 | 1,694.72 |
Diluted Weighted Average Shares | 16.94 | 16.94 | 16.94 | 16.94 |
Diluted EPS Excluding Extra Ord Items | 54.76 | 34.83 | 35.87 | 22.48 |
DPS- Common Stock Primary Issue | 42.00 | 32.00 | 32.00 | 30.00 |
Diluted Normalized EPS | 54.55 | 40.92 | 35.91 | 22.13 |
period Length | 12.00 | 12.00 | 12.00 | 12.00 |
period Type | - | - | - | - |
Unusual Expense( Income) | - | 163.30 | 10.61 | 19.82 |
Total Extraordinary Items | - | 0.00 | 3.04 | 1,313.95 |
Glaxosmithkline Pharmaceutical Dividend Glaxosmithkline Pharmaceutical Bonus Glaxosmithkline Pharmaceutical News Glaxosmithkline Pharmaceutical AGM Glaxosmithkline Pharmaceutical Rights Glaxosmithkline Pharmaceutical Splits Glaxosmithkline Pharmaceutical Board Meetings Glaxosmithkline Pharmaceutical Key Metrics Glaxosmithkline Pharmaceutical Shareholdings Glaxosmithkline Pharmaceutical Balance Sheet Glaxosmithkline Pharmaceutical Cashflow Glaxosmithkline Pharmaceutical Q1 Results Glaxosmithkline Pharmaceutical Q2 Results Glaxosmithkline Pharmaceutical Q3 Results Glaxosmithkline Pharmaceutical Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks